Story
Kioxia Reportedly Explores $10 Billion US Listing for 2027
Summary
Japanese memory chip manufacturer Kioxia Holdings is reportedly in talks with major banks for a potential U.S. listing via American Depository Receipts that could raise at least $10 billion in 2027.
Japanese memory chip manufacturer Kioxia Holdings is exploring a capital raise of at least $10 billion through a U.S. listing of American Depository Receipts (ADRs) planned for 2027, according to a Bloomberg News report. The move would grant the major semiconductor firm access to the world's largest capital market.
Details of the Potential Offering
The report, citing people familiar with the matter, states that Kioxia has held preliminary discussions with several major financial institutions about the potential offering. The banks reportedly involved in these talks include:
- Bank of America
- Goldman Sachs
- JPMorgan
An ADR listing allows shares of a foreign company to be traded on U.S. stock exchanges, making it easier for American investors to buy into the firm. The discussions are still in an early stage and the final details of the offering could change.
AdMarket Context and Implications
A $10 billion capital raise would be a significant event in the semiconductor industry, providing Kioxia with substantial funds for research, development, and expansion. The memory chip market is highly cyclical and capital-intensive, requiring massive and continuous investment in fabrication plants and new technology to remain competitive.
By pursuing a U.S. listing, Kioxia could tap into a deeper pool of capital than what may be available in its domestic market. This would bolster its financial position against global competitors in the production of NAND flash memory, which is essential for data centers, smartphones, and other digital devices.
Read next
More on Stocks
BOJ Rate Hike Nears, Pitting Japanese Financials Against Exporters
The Bank of Japan is widely expected to raise its key interest rate to a 31-year high this week, a move that is creating a sharp divide in the stock market between beneficiaries like banks and sectors facing pressure, such as exporters.
Genscript Biotech Stock Surges Over 16% on Eli Lilly AI Partnership
Shares in the Hong Kong-listed biotech firm rallied after announcing a collaboration with Eli Lilly's AI-powered drug discovery platform, a move supported by a recent capital raise focused on AI infrastructure.
Volkswagen's Seat Brand Faces Discontinuation Amid Chinese EV Pressure
Volkswagen is reportedly set to phase out its historic Spanish brand, Seat, as part of a major restructuring to combat rising competition from Chinese automakers and focus investment on its profitable, all-electric Cupra marque.
Hong Kong Biotech Sector Shows Stark Divide as Biocytogen, Genscript Post Major Gains
A small group of companies, led by Biocytogen Pharmaceuticals and Genscript Biotech, have delivered substantial one-year returns, highlighting a sharp performance gap within Hong Kong's 52-stock biotech universe where most firms remain unprofitable.